Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257456 | 0.86 | KMT2A (0.62) | NPC1RAB9AHSP90AA1ALDH1A1F2RL1 | |
| SCHEMBL4259800 | 0.84 | HTT (0.55) | HTTNPC1RAB9AHSP90AA1MAPT | |
| SCHEMBL11974036 | 0.80 | HTT (0.71) | HTTNPC1RAB9AHSP90AA1ALDH1A1 | |
| SCHEMBL26227594 | 0.80 | HTT (0.71) | HTTNPC1RAB9AHSP90AA1ALDH1A1 | |
| SCHEMBL26227589 | 0.79 | HTT (0.69) | HTTNPC1RAB9AHSP90AA1ALDH1A1 | |
| SCHEMBL31408180 | 0.79 | L3MBTL1 (0.52) | NPC1RAB9AHSP90AA1ALDH1A1KMT2A | |
| SCHEMBL28266082 | 0.78 | CA1 (0.78) | NPC1RAB9AALDH1A1F2RL1KMT2A | |
| SCHEMBL12294447 | 0.78 | CA1 (0.78) | NPC1RAB9AALDH1A1F2RL1KMT2A | |
| SCHEMBL12018996 | 0.78 | HTT (1.00) | HTTNPC1RAB9AHSP90AA1ALDH1A1 | |
| SCHEMBL19991262 | 0.78 | HTT (0.67) | HTTNPC1RAB9AHSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1710233-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | ADORA2A, ADORA2B, HTR1F | HTT 725/4885NPC1 3348/4885RAB9A 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.